Duopharma concludes supply deal for 6.4m doses of Sputnik V vaccine


Duopharma Biotech said the supply of the vaccine is subject to the approval of the vaccine by the Drug Control Authority of Malaysia, as well as other terms and conditions of supply.

KUALA LUMPUR: Duopharma Biotech Bhd has concluded the supply agreements with the Malaysian government and Russian Direct Investment Fund (RDIF) for the supply of 6.4 million doses of the Sputnik V vaccine.

In a statement, it said the supply of the vaccine is subject to the approval of the vaccine by the Drug Control Authority of Malaysia, as well as other terms and conditions of supply.

Duopharma said Sputnik V was developed by Russia’s Gamaleya National Research Institute of Epidemiology and Microbiology.

It has since been successfully registered in 68 countries across North and South America, the Middle East, Europe, Asia and Africa.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights
   

Next In Business News

New warning system to sound alarm on rainforest 'tipping points'
FOREX-US$ posts second week of gains ahead of Fed meeting
Oil price edges up in weekly rebound on forecasts for tight supplies
GLOBAL MARKETS-US stock markets hit new highs
Hotel industry’s defining moment
The toll on employment
Short Positions - Insurance, Covid-19, ESG
DPI Holdings sees virus-led opportunities
Kelington rides on semiconductor upcycle
Techna-X banks on digital trend to take it forward

Stories You'll Enjoy


Vouchers